New hope for DMD? small study tests immune drug to slow muscle decline
NCT ID NCT07475754
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the safety of a drug called rituximab in 5 boys aged 6-10 with Duchenne muscular dystrophy (DMD) who can still walk. The drug aims to lower certain immune proteins to possibly slow muscle damage. Researchers will monitor side effects and measure changes in walking and muscle strength over one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug help boys with duchenne muscular dystrophy build muscle protein?
- New drugs aim to slow muscle decline in duchenne muscular dystrophy
- AI-Powered heart scans aim to predict deadly complications in muscular dystrophy
- Wearable sensors could bring duchenne monitoring home
- Could a popular Weight-Loss drug help—or Harm—Those with duchenne muscular dystrophy?
- New drug could help boys with duchenne walk and move longer